By Steven Reinberg
WEDNESDAY, Dec. 23 (HealthDay News) -- Nearly 5 million doses of a nasal spray version of swine flu vaccine have been recalled because the vaccine loses some potency over time, but not enough to diminish its protective effect, U.S. health officials announced Tuesday.
The recall involves more than 4.6 million doses of vaccine produced by drug maker MedImmune. Most of the doses have already been used, according to the U.S. Food and Drug Administration, which added that the vaccine was strong enough when it was distributed in October and November.
Pat El-Hinnawy, an FDA spokeswoman, said the action was a "voluntary, non-safety related recall. There are no safety concerns about the vaccine. The decrease in potency is not likely to be clinically significant. Individuals who received doses from the recalled lots do not need to be revaccinated."
The recall is the second swine flu vaccine recall this month prompted by a decline in potency. Manufacturer Sanofi Pasteur recalled nearly 800,000 children's doses of injectable H1N1 swine flu vaccine because tests showed they had lost some protective effect, but not enough to require revaccination.
On Tuesday, a top U.S. health official reported that the number of cases of H1N1 swine flu infection continues to decrease and the vaccine supply is now plentiful, but too few Americans are getting inoculated.
"The H1N1 vaccine supply is getting better and better," Dr. Anne Schuchat, director of the U.S. Centers for Disease Control and Prevention's National Center for Immunization and Respiratory Diseases, said during an afternoon press conference.
While cases of swine flu infection continue to diminish around the country, the H1N1 virus is still the dominant flu strain, Schuchat said. "Disease is at a better state around the country, less virus is circulating," she said. "But still everything we are seeing in terms of the flu strains is the H1N1 virus. So it's not gone at all."
There's no way to predict whether there will be a resurgence of swine flu, which peaked nationwide in early November with 48 states reporting widespread activity.
So, "it is important to not become complacent about the ongoing risk of H1N1 influenza," Schuchat stated.
Schuchat said an estimated 111 million doses of H1N1 vaccine have been distributed so far. A CDC survey done two weeks ago found that about 46 million people had received the vaccine, with approximately 40 percent of the doses going to children, she said.
"Coverage was about twice as high in children as it was in adults," she said. "That's really good news because usually with seasonal flu there's a lot more vaccination of adults, including seniors, than children. But with the H1N1 vaccine we were targeting children because they have been so hard hit by the virus."
Unlike seasonal flu, which typically poses a much bigger threat to people aged 65 and older, the swine flu has been targeting children and young adults, probably because they have little or no immunity to the H1N1 virus, which was last seen on a pandemic level more than 50 years ago.
In a possible response to the drop in swine flu cases nationwide, a new Harvard poll found that only 40 percent of those surveyed were concerned that they or their family would come down with the flu. In a September poll, 52 percent were worried.
The poll also found that by Dec. 17, about 56 million people -- more likely children than adults -- had received the H1N1 vaccine.
"Taking those two data points together, we think right now probably at least 60 million people have been vaccinated with the H1N1 vaccine," Schuchat said.
Now is a good time to get vaccinated against the H1N1 flu, she said, because supplies are plentiful. And should there be another wave of illness, you'd be protected.
Schuchat also said that children under 10 years of age should get two doses of the vaccine to be fully protected. A recent article in the Journal of the American Medical Association suggested that children might need only one dose.